Featured Speakers

Speaker Lineup

Biotech & Pharma

Confirmed experts representing leading advanced therapies organisations are featured in the 2018 programme.

Thought Leaders

Innovation & Global Success

Sessions address innovation pathways and the conditions for global commercial success in cell and gene therapy.

The Cell & Gene Therapy World speaker faculty reflects the breadth of disciplines converging in advanced therapies, drawing together senior voices from biotech, pharma, and investment. From early-stage research through clinical translation and commercial delivery, the programme is shaped by experts who work daily across manufacturing, supply chain logistics, and market access. Their combined perspective helps frame a conversation that spans the entire therapy lifecycle, anchoring each session in practical insight rather than abstract theory and offering attendees a clear view of where the field is heading next. Manufacturing readiness remains a central theme across many speaker contributions, with experienced operators addressing scalable production, bioprocess automation, and quality systems for cell and gene products. Sessions explore how organisations are adapting facilities, standardising workflows, and building resilient partnerships that can weather regulatory shifts. Speakers bring examples from autologous and allogeneic platforms, highlighting lessons learned in yield optimisation, lot release, and cold-chain integrity, while also pointing toward emerging tools that may redefine how complex therapies are made and distributed at scale. The investment and market access dimension adds a strategic layer to the programme, as thought leaders discuss funding trends, deal structures, and the pathways that translate scientific breakthroughs into approved, reimbursed treatments. Conversations consider how reimbursement frameworks, health technology assessment, and payer engagement shape commercial viability, particularly for high-cost, one-time therapies. Speakers with backgrounds in venture capital, corporate development, and patient access share perspectives on valuation, partnership models, and the operational milestones investors look for when backing advanced therapy programmes. Beyond the core tracks, the faculty includes voices from translational science, immuno-oncology, regenerative medicine, and stem cell research, ensuring that the agenda reflects both established practice and emerging frontier science. Contributors address clinical trial design, biomarker strategy, and the regulatory dialogue needed to bring novel modalities to patients, while also considering ethical frameworks and patient experience. Together, this range of expertise creates a programme that is simultaneously rigorous, forward-looking, and grounded in the realities of bringing transformative therapies from bench to bedside.

Cell and gene therapy stands at a pivotal moment, reshaping how serious diseases are understood and treated across global healthcare systems. The field brings together advanced science and commercial ambition, drawing leaders from biotech, pharma, and investment to explore what is now possible when laboratory breakthroughs move toward real patient impact. Events in this space serve as gathering points where research meets strategy and where the future direction of medicine is actively debated and shaped by senior decision makers.

Speakers at industry gatherings typically reflect the full spectrum of the advanced therapies ecosystem, from researchers developing novel modalities to executives responsible for manufacturing scale, supply chain reliability, and market access. Their presentations often bridge scientific depth and business pragmatism, addressing how promising platforms can be translated into widely available treatments. Audience members gain insight into investment patterns, regulatory considerations, and partnership opportunities, all of which influence how quickly new therapies reach the people who need them.

Attending a focused conference offers more than updates on the latest clinical progress; it provides a structured environment for networking, collaboration, and shared learning. Carefully designed agendas combine keynote insights with breakout discussions, allowing delegates to engage with topics such as immuno-oncology, stem cell research, and translational science. For professionals seeking to remain competitive in a fast-moving sector, participation in these events helps clarify emerging trends and build the relationships that often determine which innovations succeed beyond the laboratory.

Executive Voices

Market Access & Investment

Speakers explore market access strategy and the investment case for advanced therapies products.